WAVE Life Sciences LtdNASDAQ:WVE
- LAST PRICE6.1900
- TODAY'S CHANGE (%)0.2900 (4.9153%)
- Bid / Lots6.1800/ 1
- Ask / Lots6.2000/ 3
- Open / Previous Close5.9300 / 5.9000
- Day Range
- 52 Week Range
- Volume225,442
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | WVE |
|---|---|---|
| 09:32 ET | 17767 | 5.92 |
| 09:34 ET | 500 | 5.895 |
| 09:36 ET | 3142 | 5.88 |
| 09:38 ET | 1000 | 5.85 |
| 09:39 ET | 200 | 5.82 |
| 09:41 ET | 17467 | 5.93 |
| 09:43 ET | 500 | 5.96 |
| 09:45 ET | 225 | 5.97 |
| 09:50 ET | 225 | 5.9899 |
| 09:54 ET | 1300 | 5.9897 |
| 09:57 ET | 200 | 5.99 |
| 09:59 ET | 100 | 5.99 |
| 10:01 ET | 418 | 6 |
| 10:03 ET | 192 | 5.99 |
| 10:08 ET | 11586 | 6.02 |
| 10:10 ET | 4599 | 6 |
| 10:12 ET | 600 | 6.01 |
| 10:17 ET | 100 | 6.005 |
| 10:19 ET | 312 | 6.005 |
| 10:21 ET | 100 | 6.005 |
| 10:24 ET | 2103 | 5.99 |
| 10:26 ET | 400 | 6 |
| 10:32 ET | 413 | 6.004 |
| 10:33 ET | 3528 | 6 |
| 10:35 ET | 200 | 6 |
| 10:37 ET | 269 | 5.9939 |
| 10:39 ET | 100 | 6 |
| 10:42 ET | 332 | 6.01 |
| 10:46 ET | 200 | 6.01 |
| 10:48 ET | 2500 | 6.01 |
| 10:50 ET | 300 | 6 |
| 10:53 ET | 5315 | 6 |
| 10:57 ET | 100 | 6 |
| 11:02 ET | 1013 | 6.01 |
| 11:11 ET | 75884 | 6.015 |
| 11:13 ET | 1614 | 6.02 |
| 11:15 ET | 2446 | 6.03 |
| 11:18 ET | 7421 | 6.11 |
| 11:20 ET | 100 | 6.108 |
| 11:24 ET | 3534 | 6.13 |
| 11:27 ET | 100 | 6.12 |
| 11:29 ET | 300 | 6.12 |
| 11:31 ET | 700 | 6.12 |
| 11:36 ET | 627 | 6.11 |
| 11:38 ET | 200 | 6.11 |
| 11:40 ET | 6148 | 6.14 |
| 11:42 ET | 4565 | 6.15 |
| 11:44 ET | 1766 | 6.158 |
| 11:45 ET | 200 | 6.155 |
| 11:47 ET | 100 | 6.155 |
| 11:49 ET | 530 | 6.1505 |
| 11:51 ET | 3105 | 6.2 |
| 11:54 ET | 8592 | 6.185 |
| 11:56 ET | 229 | 6.19 |
| 11:58 ET | 1510 | 6.17 |
| 12:00 ET | 500 | 6.15 |
| 12:02 ET | 1600 | 6.19 |
May 15, 2024
DJ Wave Life Sciences Initiated at Overweight by Wells Fargo, from 8:29AM ET on Wednesday May 15, 2024 by Dow Jones
8:29AM ET on Wednesday May 15, 2024 by Dow Jones
May 9, 2024
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update, from 7:30AM ET on Thursday May 09, 2024 by Dow Jones
7:30AM ET on Thursday May 09, 2024 by Dow Jones*DJ Wave Life Sciences 1Q Loss/Shr 24c >WVE, from 7:30AM ET on Thursday May 09, 2024 by Dow Jones
7:30AM ET on Thursday May 09, 2024 by Dow JonesPress Release: Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer, from 7:00AM ET on Thursday May 09, 2024 by Dow Jones
7:00AM ET on Thursday May 09, 2024 by Dow JonesWave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer, from 7:00AM ET on Thursday May 09, 2024 by Dow Jones
7:00AM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
WAVE Life Sciences Ltd | 721.7M | -12.0x | --- |
SAGE Therapeutics Inc | 722.8M | -1.4x | --- |
Regenxbio Inc | 788.6M | -2.7x | --- |
Zymeworks Inc | 663.2M | -5.1x | --- |
Alector Inc | 529.2M | -3.8x | --- |
Entrada Therapeutics Inc | 504.7M | 24.1x | --- |
Company Information
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
Contact Information
- Headquarters
- 7 Straits View #12-00, Marina One East Tower, Singapore 018936
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Christian Henry
- President, Chief Executive Officer, Director
- Paul Bolno
- Chief Financial Officer
- Kyle Moran
- Senior Vice President, Corporate Development & Portfolio Management
- Christopher Francis
- Chief Technology Officer, Head - Platform Discovery Sciences
- Chandra Vargeese
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $721.7M |
|---|---|
Revenue (TTM) | $112.9M |
Shares Outstanding | 122.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.04 |
EPS | $-0.52 |
Book Value | $0.40 |
P/E Ratio | -12.0x |
Price/Sales (TTM) | 6.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -63.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
